Karaali Cem, Emiroğlu Mümin, Değirmenci Mustafa, Keser Murat, Salimoğlu Semra, Kelten Talu Canan
Department of General Surgery, İzmir Faculty of Medicine, University of Health Sciences Turkey, İzmir, Turkey.
Department of Medical Pathology, İzmir Faculty of Medicine, University of Health Sciences Turkey, İzmir, Turkey.
Eur J Breast Health. 2023 Dec 27;20(1):19-24. doi: 10.4274/ejbh.galenos.2023.2023-6-3. eCollection 2024 Jan.
Estrogen receptor (ER) expression is an immunohistochemical marker that is examined in all invasive breast cancers and has prognostic and predictive value. ER-positive breast cancers refer to those that show positivity for ER at 1% cellular expression or higher. The American Society of Clinical Oncology/College of American Pathologists guidelines suggest using the term "low ER-positive breast cancer" for tumors with ER expression between 1% and 10%. Low ER-positive breast cancers exhibit similarities, in terms of disease-free survival and overall survival rates, to triple-negative breast cancers (TNBCs) rather than ER-positive breast cancers. In this study, our aim was to compare the clinicopathological characteristics of low ER-positive breast cancer cases diagnosed and followed in our clinic with TNBCs.
A total of 26 cases of low ER-positive breast cancer diagnosed at University of Health Sciences Turkey, İzmir Tepecik Training and Research Hospital between 2010 and 2016 were retrieved from hospital records. The relevant histopathology slides and blocks were retrieved and re-evaluated retrospectively through microscopic examination. Thirteen cases that met the criteria were included in the study. Additionally, a consecutive series of 13 TNBC cases that did not receive neoadjuvant treatment within the same time period were identified.
In the low ER-positive group, the presence of tumor necrosis, as well as histological grade, nuclear grade and Ki-67 proliferation index were significantly lower compared to the TNBC group. Ductal carcinoma (DCIS) was significantly more common in the low ER-positive group compared to the TNBC group. There were no significant differences between the two groups in terms of tumor size, histological tumor type, axillary lymph node involvement, tumor margins, peritumoral and intratumoral inflammation, local recurrence, distant metastasis, survival, and other characteristics.
Although our study consisted of a small number of cases, some features showed significant differences between low ER-positive breast cancers and TNBCs. Histological and nuclear grades, as well as the presence of a DCIS component, were associated with low ER-positive breast cancer. In contrast, the presence of tumor necrosis, as well as Grade 3 features and a high Ki-67 proliferation index indicated TNBC.
雌激素受体(ER)表达是一种免疫组化标志物,在所有浸润性乳腺癌中均会检测,具有预后和预测价值。ER阳性乳腺癌是指那些细胞表达率为1%或更高时显示ER阳性的乳腺癌。美国临床肿瘤学会/美国病理学家学会指南建议,对于ER表达在1%至10%之间的肿瘤,使用“低ER阳性乳腺癌”这一术语。低ER阳性乳腺癌在无病生存率和总生存率方面,与三阴性乳腺癌(TNBC)更为相似,而非ER阳性乳腺癌。在本研究中,我们的目的是比较在我们诊所诊断并随访的低ER阳性乳腺癌病例与TNBC的临床病理特征。
从土耳其伊兹密尔特佩奇克培训与研究医院健康科学大学2010年至2016年期间诊断的低ER阳性乳腺癌病例中,共检索出26例,并从医院记录中获取相关组织病理学切片和蜡块,通过显微镜检查进行回顾性重新评估。符合标准的13例病例纳入研究。此外,确定了同一时期连续的13例未接受新辅助治疗的TNBC病例。
在低ER阳性组中,与TNBC组相比,肿瘤坏死的存在以及组织学分级、核分级和Ki-67增殖指数显著更低。与TNBC组相比,导管原位癌(DCIS)在低ER阳性组中明显更常见。两组在肿瘤大小、组织学肿瘤类型、腋窝淋巴结受累情况、肿瘤边缘、瘤周和瘤内炎症、局部复发、远处转移、生存率及其他特征方面无显著差异。
尽管我们的研究病例数量较少,但低ER阳性乳腺癌与TNBC之间的一些特征存在显著差异。组织学和核分级以及DCIS成分的存在与低ER阳性乳腺癌相关。相比之下,肿瘤坏死的存在以及3级特征和高Ki-67增殖指数提示为TNBC。